5vl3 - Revision history

OCA at 08:04, 27 November 2019

OCA — Wed, 27 Nov 2019 08:04:48 GMT

←Older revision		Revision as of 08:04, 27 November 2019
Line 1:		Line 1:

	==CD22 d1-d3 in complex with therapeutic Fab Epratuzumab==		==CD22 d1-d3 in complex with therapeutic Fab Epratuzumab==
-	<StructureSection load='5vl3' size='340' side='right' caption='[[5vl3]], [[Resolution\|resolution]] 3.10Å' scene=''>	+	<StructureSection load='5vl3' size='340' side='right'caption='[[5vl3]], [[Resolution\|resolution]] 3.10Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[5vl3]] is a 12 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human] and [http://en.wikipedia.org/wiki/Lk3_transgenic_mice Lk3 transgenic mice]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5VL3 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5VL3 FirstGlance]. <br>		<table><tr><td colspan='2'>[[5vl3]] is a 12 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human] and [http://en.wikipedia.org/wiki/Lk3_transgenic_mice Lk3 transgenic mice]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5VL3 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5VL3 FirstGlance]. <br>
Line 25:		Line 25:
	</StructureSection>		</StructureSection>
	[[Category: Human]]		[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: Lk3 transgenic mice]]		[[Category: Lk3 transgenic mice]]
	[[Category: Ereno-Orbea, J]]		[[Category: Ereno-Orbea, J]]

OCA at 07:49, 6 December 2017

OCA — Wed, 06 Dec 2017 07:49:15 GMT

←Older revision		Revision as of 07:49, 6 December 2017
Line 3:		Line 3:
	<StructureSection load='5vl3' size='340' side='right' caption='[[5vl3]], [[Resolution\|resolution]] 3.10Å' scene=''>		<StructureSection load='5vl3' size='340' side='right' caption='[[5vl3]], [[Resolution\|resolution]] 3.10Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5vl3]] is a 12 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5VL3 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5VL3 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5vl3]] is a 12 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human] and [http://en.wikipedia.org/wiki/Lk3_transgenic_mice Lk3 transgenic mice]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5VL3 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5VL3 FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5vkj\|5vkj]], [[5vkk\|5vkk]], [[5vkm\|5vkm]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5vkj\|5vkj]], [[5vkk\|5vkk]], [[5vkm\|5vkm]]</td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">CD22, SIGLEC2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5vl3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5vl3 OCA], [http://pdbe.org/5vl3 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5vl3 RCSB], [http://www.ebi.ac.uk/pdbsum/5vl3 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5vl3 ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5vl3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5vl3 OCA], [http://pdbe.org/5vl3 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5vl3 RCSB], [http://www.ebi.ac.uk/pdbsum/5vl3 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5vl3 ProSAT]</span></td></tr>
	</table>		</table>
Line 23:		Line 24:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
		+	[[Category: Lk3 transgenic mice]]
	[[Category: Ereno-Orbea, J]]		[[Category: Ereno-Orbea, J]]
	[[Category: Julien, J P]]		[[Category: Julien, J P]]

OCA at 06:44, 11 October 2017

OCA — Wed, 11 Oct 2017 06:44:52 GMT

←Older revision		Revision as of 06:44, 11 October 2017
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 5vl3 is ~~ON HOLD~~	+	==CD22 d1-d3 in complex with therapeutic Fab Epratuzumab==
		+	<StructureSection load='5vl3' size='340' side='right' caption='[[5vl3]], [[Resolution\|resolution]] 3.10Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[5vl3]] is a 12 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5VL3 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5VL3 FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
		+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5vkj\|5vkj]], [[5vkk\|5vkk]], [[5vkm\|5vkm]]</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5vl3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5vl3 OCA], [http://pdbe.org/5vl3 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5vl3 RCSB], [http://www.ebi.ac.uk/pdbsum/5vl3 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5vl3 ProSAT]</span></td></tr>
		+	</table>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/CD22_HUMAN CD22_HUMAN]] Mediates B-cell B-cell interactions. May be involved in the localization of B-cells in lymphoid tissues. Binds sialylated glycoproteins; one of which is CD45. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site can be masked by cis interactions with sialic acids on the same cell surface. Upon ligand induced tyrosine phosphorylation in the immune response seems to be involved in regulation of B-cell antigen receptor signaling. Plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules.
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	CD22 maintains a baseline level of B-cell inhibition to keep humoral immunity in check. As a B-cell-restricted antigen, CD22 is targeted in therapies against dysregulated B cells that cause autoimmune diseases and blood cancers. Here we report the crystal structure of human CD22 at 2.1 A resolution, which reveals that specificity for alpha2-6 sialic acid ligands is dictated by a pre-formed beta-hairpin as a unique mode of recognition across sialic acid-binding immunoglobulin-type lectins. The CD22 ectodomain adopts an extended conformation that facilitates concomitant CD22 nanocluster formation on B cells and binding to trans ligands to avert autoimmunity in mammals. We structurally delineate the CD22 site targeted by the therapeutic antibody epratuzumab at 3.1 A resolution and determine a critical role for CD22 N-linked glycosylation in antibody engagement. Our studies provide molecular insights into mechanisms governing B-cell inhibition and valuable clues for the design of immune modulators in B-cell dysfunction.The B-cell-specific co-receptor CD22 is a therapeutic target for depleting dysregulated B cells. Here the authors structurally characterize the ectodomain of CD22 and present its crystal structure with the bound therapeutic antibody epratuzumab, which gives insights into the mechanism of inhibition of B-cell activation.

-	~~Authors~~:	+	Molecular basis of human CD22 function and therapeutic targeting.,Ereno-Orbea J, Sicard T, Cui H, Mazhab-Jafari MT, Benlekbir S, Guarne A, Rubinstein JL, Julien JP Nat Commun. 2017 Oct 2;8(1):764. doi: 10.1038/s41467-017-00836-6. PMID:28970495<ref>PMID:28970495</ref>

-	~~Description~~:	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	[[Category: ~~Unreleased Structures~~]]	+	</div>
		+	<div class="pdbe-citations 5vl3" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Ereno-Orbea, J]]
		+	[[Category: Julien, J P]]
		+	[[Category: Sicard, T]]
		+	[[Category: B cell]]
		+	[[Category: Fab]]
		+	[[Category: Immune system]]
		+	[[Category: Siglec]]
		+	[[Category: Therapeutic antibody]]

OCA: Protected "5vl3" [edit=sysop:move=sysop]

OCA — Thu, 04 May 2017 11:26:00 GMT

Protected "5vl3" [edit=sysop:move=sysop]

←Older revision

Revision as of 11:26, 4 May 2017

OCA: New page: '''Unreleased structure''' The entry 5vl3 is ON HOLD Authors: Description: Category: Unreleased Structures

OCA — Thu, 04 May 2017 11:25:59 GMT

New page: '''Unreleased structure''' The entry 5vl3 is ON HOLD Authors: Description: Category: Unreleased Structures

New page

'''Unreleased structure'''

The entry 5vl3 is ON HOLD

Authors:

Description:
[[Category: Unreleased Structures]]